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MyD88 has a modular organization, an N-terminal
death domain (DD) related to the cytoplasmic signaling
domains found in many members of the tumor necrosis
factor receptor (TNF-R) superfamily, and a C-terminal
Toll domain similar to that found in the expanding fam-
ily of Toll/interleukin-1-like receptors (IL-1R). This dual
domain structure, together with the following observa-
tions, supports a role for MyD88 as an adapter in IL-1
signal transduction; MyD88 forms homodimers in vivo
through DD-DD and Toll-Toll interactions. Overexpres-
sion of MyD88 induces activation of the c-Jun N-termi-
nal kinase (JNK) and the transcription factor NF-kB
through its DD. A point mutation in MyD88, MyD88-lpr
(F56N), which prevents dimerization of the DD, also
blocks induction of these activities. MyD88-induced
NF-kB activation is inhibited by the dominant negative
versions of TRAF6 and IRAK, which also inhibit IL-1-
induced NF-kB activation. Overexpression of MyD88-lpr
or MyD88-Toll (expressing only the Toll domain) acted
to inhibit IL-1-induced NF-kB and JNK activation in a
293 cell line overexpressing the IL-1RI. MyD88 coimmu-
noprecipitates with the IL-1R signaling complex in an
IL-1-dependent manner.
The myeloid differentiation protein (MyD88) has no known
biological function (1). Sequence analysis, however, suggests
that it may have signaling capabilities; MyD88 is predicted to
have a modular organization consisting of an N-terminal death
domain (DD)1 separated by a short linker from a C-terminal
Toll domain (2–7).
The N-terminal DD is related to a motif of approximately 90
amino acids that was initially defined as the region of similar-
ity between the cytoplasmic tails of the FAS/Apo1/CD95 and
TNF receptors required for their induction of cytotoxic signal-
ing (8, 9). The DD, which has in recent years been found in
many additional proteins, is now known to mediate protein-
protein interactions with other DD sequences forming either
homo- or heterodimers (10). This property is utilized by many
members of the TNF superfamily (i.e. FAS, TNF-R1, DR3/
Apo3/WSL-1/TRAMP, and TRAIL-Rs 1 and 2), in response to
ligand activation, to establish interactions that form the foun-
dation for building signaling complexes that can induce re-
sponses such as cytotoxicity, activation of the c-Jun N-terminal
kinase (JNK)/stress-activated protein kinases, and/or activa-
tion of the transcription factor nuclear factor kB (NF-kB) (11).
MyD88’s C-terminal Toll domain is comprised of approxi-
mately 130 amino acids (5). This domain was originally de-
scribed based on the homology between the cytoplasmic signal-
ing regions of the Drosophila melanogaster transmembrane
protein Toll and the IL-1RI, but is now found in an expanding
family of proteins, most of which are cell surface receptors (5,
12–14). MyD88 is the only reported mammalian protein with a
Toll domain that is not predicted to be a transmembrane. The
Toll domain lacks an intrinsic signaling capacity and thereby
transduces signals by recruiting associated proteins. It is not
known whether Toll domains function in an analogous manner
to DDs by mediating Toll-Toll interactions. However, the dis-
covery that the Toll-containing IL-1 receptor accessory protein
(IL-1RAcP) acts as a co-receptor for IL-1RI and is an indispen-
sable molecule in the IL-1RI signal transduction complex sug-
gests that interactions between like domains may have a role in
the formation of signaling complexes (15–17).
In recent years some of the proteins involved in the proximal
signaling events associated with IL-1RI-induced activation of
NF-kB have been identified. This has revealed the striking
similarity between the IL-1RI and Drosophila Toll signaling
pathways. Toll induces Dorsal activation (a homolog of NF-kB)
which like NF-kB is normally held in an inactive state in the
cytoplasm by the IkB-like inhibitory protein, Cactus. Following
stimulation, these inhibitory proteins become phosphorylated,
ubiquinated, and degraded via proteasome-mediated path-
ways, which frees NF-kB/Dorsal to translocate into the nucleus
and begin transcription. The Drosophila Ser/Thr kinase Pelle is
believed to be involved in the phosphorylation of Cactus (18). In
the IL-1 pathway, a Ser/Thr kinase that is rapidly recruited to
the IL-1RI complex, within seconds of IL-1 binding, has re-
cently been identified (19). This kinase, the IL-1 receptor asso-
ciated kinase (IRAK), is highly homologous to Pelle but not to
other mammalian Ser/Thr kinases. Interestingly, both Pelle
and IRAK have N-terminal DDs (19). In the Toll pathway a
second protein exists with a DD, Tube, which regulates the
activity of Pelle through DD-DD interactions (20–22). Addi-
tional DD-containing adapter molecules may, therefore, also
exist in the IL-1 pathway. With its dual domain organization
MyD88 has ideal properties to function as an adapter linking Toll
and death modules. Here, we examine this intriguing possibility
by analyzing the functional role(s) of the MyD88 domains.
* The costs of publication of this article were defrayed in part by the
payment of page charges. This article must therefore be hereby marked
“advertisement” in accordance with 18 U.S.C. Section 1734 solely to
indicate this fact.
§ Supported by the Human Frontier Science Program.
§§ To whom correspondence should be addressed: Institute of Bio-
chemistry, University of Lausanne, Ch. des Boveresses 155, CH-1066
Epalinges, Switzerland. Tel.: 41 21 692 5738; Fax: 41 21 692 5705;
E-mail: jurg.tschopp@ib.unil.ch.
1 The abbreviations used are: DD, death domain; JNK, Jun N-termi-
nal kinase; IL, interleukin; IL-1R, interleukin 1 receptor; AcP, acces-
sory protein; IRAK, IL-1 receptor-associated kinase; NF, nuclear factor;
GST, glutathione S-transferase; TNF, tumor necrosis factor; DTT, di-
thiothreitol; PBS, phosphate-buffered saline; PAGE, polyacrylamide gel
electrophroresis; PCR, polymerase chain reaction; HIV, human immu-
nodeficiency virus; Luc, luciferase; b-gal, b-galactosidase; db, DNA
binding.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 273, No. 20, Issue of May 15, pp. 12203–12209, 1998
© 1998 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A.
This paper is available on line at http://www.jbc.org 12203
 by guest on M
ay 11, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
EXPERIMENTAL PROCEDURES
Cell Culture—The 293T human embryonic kidney cell line or 293
cells (ATCC CRL 1573) were cultured in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal calf serum and penicillin/strep-
tomycin (100 mg/ml of each) and grown in 5% CO2 at 37 °C.
Northern Blot Analysis—Isolation of total RNA from various mouse
tissues was carried out as described elsewhere (23, 24). A MyD88
antisense RNA probe was synthesized by in vitro transcription in the
presence of 12.5 mM a-[32P]UTP (400 Ci/mmol; Amersham Interna-
tional, Amersham, UK). Following extensive washing of the Northern
blot, the membrane was exposed to x-ray films (XAR; Eastman Kodak
Co.) for 4 days.
Expression Vectors—Mouse MyD88 was first identified as a tran-
script encoding a protein of 243 residues (1). However, since then
several lines of evidence suggest that the transcript for MyD88 is 53
amino acids longer (predicted molecular mass of ;33 kDa) and starts at
Met minus 53 (4, 25, 26). To obtain full-length mMyD88 cDNA, total
RNA isolated from murine bone marrow was reverse transcribed using
a cDNA cycle kit from Promega, amplified by PCR (JT478 59-gtt ctc cat
acc ctt ggt-39 and JT318 59-cgc atc agt ctc atc ttc-39) and subcloned into
PCRII TA-cloning vector (InvitroGen). A modified pCRIII (InvitroGen)
mammalian expression vector was constructed by cloning a Kozak
consensus sequence (GCCACC) and the Flag epitope (MDYKDDDK)
between the BamHI and EcoRI sites of PCR-III to yield pMet-Flag-V63.
MyD88 was subcloned as an EcoRI fragment into pMet-Flag-V63 to give
pFlag-MyD88 or into pMet-Myc (27) to give pMyc-MyD88. MyD88-
F56N (referred to as MyD88-lpr) and MyD88 lacking the DD (MyD88-
DDD) were generated by PCR using the following primers: MyD88-lpr,
JT317 59-gga gat ggg caa cga gta ct-39 and JT318; MyD88-DDD, JT386
59-cga gga gga ctg cca gaa-39 and JT318 and then cloned as EcoRI
fragments into pMet-Flag-V63. MyD88 encoding the Toll domain (ami-
no acids 161–296) and deletions within this region, Toll-N (amino acids
161–296), Toll-C (amino acids 230–296), and Toll-D282–296 (amino
acids 161–281) were amplified by PCR with the following primers: Toll,
JT749 59-ttc gat gcc ttt atc tgc-39 and JT318; Toll-N, JT749 and JT752
59-cta gct ctg tag ata atc-39; Toll-C, JT751 59-agc aag gaa tgt gac ttc-39
and JT318 and Toll-D282–296, with primers JT749 and JT750 59-cta
ggt gca agg gtt ggt-39. MyD88-N was made by removing the EcoRV
fragment from pFlag-MyD88. All constructs were confirmed by se-
quencing. Yeast expression vectors were prepared by cloning DNA for
MyD88 and the deletion mutants (indicated above) as EcoRI fragment
into the LexA DNA-binding domain vector, pBTM116 (28), GAL4 DNA-
binding domain vector, pGBT9 (CLONTECH), and into the GAL4 acti-
vation domain vector, pGAD10 (CLONTECH).
The following plasmids were obtained from the indicated sources:
NF-kB luc (Victor Jongeneel, Lausanne, CH); Myc-IL-1RI, IRAK and
IL-1RAcP (Keith Ray and Filippo Volpe, Glaxo Welcome, UK); Flag-
JNK (Christian Widman, Denver, CO); TRAF6 (287–522) and TRAF2
(87–501) (Harold Wajant, Stuttgard, Germany). IRAK encoding the DD
(amino acids 1–217) was amplified by PCR with the following primers:
JT651 59-gaa ttc atg gcc ggg ggg ccg-39 and JT902 59-tca ctt gag ctc ctc
cga gaa gtt-39.
Yeast Two-Hybrid Interaction Analysis—Protein/protein interactions
were analyzed by cotransforming plasmids encoding the LexA-DNA
binding (LexA-db) fusion proteins or GAL4-DNA binding (GAL4-db)
fusion proteins with plasmids encoding the various GAL4-activation
domain (GAL4-ab) fusion proteins (2.5 mg of each plasmid) into Saccha-
romyces cerevisiae strain CTY10–5d (used with LexA-db constructs) or
Y190 (used with GAL4-db constructs) following the Two-Hybrid System
protocol (CLONTECH). Filter lift assays for colony color development
were done as described previously (29).
Generation of Glutathione S-Transferase (GST)-MyD88 and in Vitro
Binding Assays—MyD88 was cloned as an EcoRI fragment into pGEX-
4T-1 (Pharmacia Biotech Inc.). GST fusion proteins were induced with
isopropyl-thiogalactoside and purified on glutathione-agarose beads as
described elsewhere (30). 35S-Labeled MyD88 and mutant versions
were generated with the TNT T7 coupled reticulocyte lysate system
(Promega) according to the manufacturer’s instructions. Following
translation 35S-labeled reticulocyte lysates (2 ml) were incubated with
20 ml of GST-MyD88 (;3 mg) bound to the GST beads in 1 ml of binding
buffer (50 mM HEPES, pH 7.6, 250 mM NaCl, 0.1% Nonidet P-40, 5 mM
EDTA) and incubated for 1 h at 4 °C as described previously (31). After
incubation the GST beads were pelleted for 2 min at low speed and then
washed six times with binding buffer. The washed beads were boiled in
SDS sample buffer and loaded onto 12% SDS-polyacrylamide gels which
were enhanced by incubation in En3HanceTM (Du Pont) prior to fluo-
rography at 280 °C.
Antibodies/Western Blot Analysis—Monoclonal antibodies used for
immunoprecipitations and Western blotting include anti-Flag M2 anti-
body (Kodak Biosciences) used at a concentration of 5 mg/ml, antibody
against the Myc epitope (9E10, Sigma) used at a concentration of 1
mg/ml, anti-VSV antibody (Sigma) used at a dilution of 1:20,000, anti-
JNK2 antibody (Santa Cruz Biotechnology) used at a dilution of 1:1000,
and antibodies against the active phosphorylated form of JNK, Anti-
ACTIVETM (Promega) used at a dilution of 1:5000. Antiserum against
MyD88 (AL126) was generated using a peptide spanning amino acids
54–77 (MGFEYLEIRELETRPDPTRSLLDA), which was synthesized
using the multiple antigen technology (31). The antiserum was affinity-
purified on the MyD88 peptide coupled to CNBr-Sepharose 4B (Phar-
macia) and used at a dilution of 1:500. For Western analysis protein
extracts were separated by SDS-PAGE and transferred to Hybond ECL
nitrocellulose membrane (Amersham Life Science). Blots were incu-
bated with the antibodies in blocking buffer (PBS, 0.5% Tween 20, 5%
skim milk) followed by horseradish peroxidase-conjugated goat anti-
mouse IgG or anti-rabbit IgG (Jackson ImmunoResearch Labs Inc.)
diluted 1:2000 in blocking buffer. Bound antibody was detected using
the enhanced chemiluminescence kit (Amersham International) accord-
ing to the protocol of the manufacturer.
Gel Permeation Chromatography—293T cells (1 3 107) were tran-
siently transfected with Flag-MyD88 (12 mg). 24 h after transfection the
cells were harvested and lysed in PBS (300 ml) containing CompleteTM
protease inhibitor mixture by mild sonication (four times for 5 s each).
The soluble cellular extract (150 ml) was mixed with the internal stand-
ards catalase and ovalbumin, then loaded onto a Superdex-200
HR10/30 column, and the proteins were eluted in PBS at 0.5 ml/min.
Every second fraction (250 ml) was precipitated with trichloroacetic acid
and then analyzed by Western blotting with anti-Flag antibody. The
column was calibrated with the following standard proteins: thyroglob-
ulin (669 kDa), ferritin (440 kDa), catalase (232 kDa), aldolase (158
kDa), bovine serum albumin (67 kDa), ovalbumin (43 kDa), chymot-
rypsinogen A (25 kDa), and ribonuclease A (13.7 kDa).
Tissue Extracts, and Coimmunoprecipitation—Tissue extracts were
prepared from BalbC mice by homogenization in PBS containing 1%
Nonidet P-40 and CompleteTM protease inhibitor mixture (Boehringer
Mannheim). The extracts were spun at 13,000 rpm for 20 min at 4 °C,
and the supernatants were collected for Western blotting analysis.
Cellular extracts were obtained from 293T cells harvested 26 h after
transfection and lysed as described previously (27). For coimmunopre-
cipitation of MyD88 and its deletion mutants, transfected 293T cells
(1 3 106), were lysed in 200 ml of lysis buffer (50 mM Tris, pH 7.8, 150
FIG. 1. Expression of MyD88 in mouse tissues. A, Northern blot
analysis of total RNA (5 mg/lane) from various mouse tissues hybridized
with an antisense MyD88 RNA probe. The lower panel shows ethidium
bromide staining of the 28 S rRNA species. B, specificity control of
affinity-purified antibody against MyD88. A blot containing cell ex-
tracts (25 mg) from 293T cells transfected with Flag-MyD88 or with an
empty vector was probed with affinity-purified anti-MyD88 antibody
and then reprobed with anti-Flag antibodies. C, Western blot analysis
of various mouse tissues. A blot containing 30 mg of protein extracted
from the indicated tissues was probed with affinity-purified anti-
MyD88. The positions of the molecular mass standards (in kDa) are
shown on the left.
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mM NaCl, 0.1% Nonidet P-40, 5 mM EDTA). The lysates were incubated
with 3 mg of anti-Flag agarose at 4 °C overnight. The agarose beads
were washed five times with lysis buffer, and the precipitated proteins
were then fractionated on 12% SDS-PAGE and analyzed by Western
blotting. To detect MyD88 associated with the IL-1RI complex, 3 3 106
transfected 293T cells were first treated with IL-1b (200 ng/ml) for 3
min, the complex was then precipitated by the addition of 3 mg of
anti-Flag M2 antibody to the cellular lysates (500 ml) for 3 h and then
10 ml of protein G-agarose for an additional hour, and MyD88 was
detected by Western analysis. Cells were treated with IL-1b and lyzed
as described elsewhere (19). Protein content of tissue and cell extracts
was determined using the BCA protein determination kit (Pierce).
NF-kB Activation Assays—Electrophoretic mobility shift assays were
carried out as described previously (32). In brief, total cellular extracts
were prepared from transfected 293 cells (2 3 106) using a high salt
detergent buffer (Totex) (20 mM Hepes, pH 7.9, 350 mM NaCl, 20% (w/v)
glycerol, 1% (w/v) Nonidet P-40, 1 mM MgCl2, 0.5 mM EDTA, 0.1 mM
EGTA, 0.5 mM DTT, 0.1% phenylmethylsulfonyl fluoride, 1% aprotinin).
The cells were harvested by centrifugation, washed once in ice-cold PBS
(Sigma), and resuspended in four cell volumes of Totex buffer. After 30
min on ice, the lysates were centrifuged for 5 min at 13,000 3 g at 4 °C.
The protein content of the supernatant was determined, and equal
amounts of protein (10–20 mg) were added to a reaction mixture con-
taining 20 mg of bovine serum albumin (Sigma), 2 mg of poly(dI-dC)
(Boehringer Mannheim), 2 ml of buffer D1 (20 mM Hepes, pH 7.9, 20%
glycerin, 100 mM KCl, 0.5 mM EDTA, 0.25% Nonidet P-40, 2 mM DTT,
0.1% phenylmethylsulfonyl fluoride), 4 ml of buffer F (20% Ficoll 400,
100 mM Hepes, 300 mM KCl, 10 mM DTT, 0.1% phenylmethylsulfonyl
fluoride), and 100,000 cpm (Cerenkov) of a 32P-labeled oligonucleotide
in a final volume of 20 ml. For the supershift assays, 1.0 ml of antibody
was added to the reaction simultaneously with the probe and incubated
as described. Anti-p65 antibodies were purchased from Santa Cruz
Biotechnology. The NF-kB oligonucleotides (Promega) was labeled us-
ing g-[32P]ATP (3000 Ci/mmol; Amersham) and T4 polynucleotide ki-
nase (Promega).
For the NF-kB reporter assays, 2 3 105 293T or 293 Myc-IL-1RI cells
were transfected by the calcium phosphate method. A stable cell line
expressing the Myc-tagged IL-1RI cells was obtained by transfection of
293 with a Myc-IL-1RI expression plasmid and selection with G418 (600
mg/ml) (Life Technologies, Inc.). Drug-resistant clones were tested for
expression of Myc-IL-1RI by Western analysis with Myc antibody. The
cells were harvested 24–42 h after transfection and lysed with 400 ml of
lysis buffer (1% Triton X-100, 25 mM glycylglycine, pH 7.8, 14 mM
MgSO4, 4 mM EGTA, 1 mM DTT). Where indicated IL-1b (Boehringer
Mannheim) (10 ng/ml) was added to the medium 36 h after transfection
for 6 h before the cells were harvested. Aliquots of cell lysates (1–5 ml)
were mixed with 100 ml of luciferase assay reagent (Promega), and the
luciferase activity was determined using a biocounter M2500 luminom-
eter (Inotech, Zurich). b-Galactosidase activity was determined in a
mixture containing 50 ml of cell extract and 50 ml of a buffer containing
the substrate o-nitrophenyl-b-D-galactopyranoside (Sigma). Samples
were incubated at 37 °C until a yellow color developed, and then the
absorbance was determined at 405 nm. These values were used to
normalize transfection efficiency.
Detection of JNK Activity—293T cells transfected with the Flag-JNK
vector and the indicated expression plasmids were harvested 24 h after
transfection and lysed in 0.1% Nonidet P-40 lysis buffer. 38 h after
transfection of 293 Myc-IL-1RI, 20 ng/ml IL-1b was added for an addi-
tional 7 h before the cells were harvested and lysed as above. Equiva-
lent amounts of protein were separated by 12% SDS-PAGE and sub-
jected to Western analysis with anti-JNK2 antibody or with Anti-
ACTIVETM antibody (Promega). Kinase assays were performed on
transfected cells (1 3 10 6) serum-starved for 16 h. JNK was immuno-
precipated from cell extracts with 5 mg of anti-Flag antibody for 2 h at
4 °C. The washed Sepharose beads were incubated with 1 mg of GST-
JNK (Santa Cruz) in 40 ml of kinase buffer containing 20 mM HEPES
(pH 7.5), 20 mM b-glycerophosphate, 10 mM p-nitrophenyl phosphate,
10 mM MgCl2, 1 mM DTT, and 50 mM Na3VO4) at 30 °C for 20 min. The
reactions were separated by SDS-PAGE and transferred to nitrocellu-
lose. To ensure that comparable levels of JNK were present the mem-
brane was probed with anti-Flag antibodies, following autoradiography.
RESULTS
Expression of MyD88—The murine MyD88 transcript was
originally reported to be expressed in myeloid precursor en-
riched murine bone marrow cells and not in nonmyeloid tissues
(1). Since then, MyD88 mRNA has been detected in a number
of nonmyeloid cell lines (4, 26). Here we extend this analysis to
show that the murine MyD88 transcript (approximately 2.2
kilobase pairs) is present in many tissues, in fact in all tissues
tested except for the brain (Fig. 1A). In order to examine the
expression pattern of the MyD88 protein, we generated anti-
bodies against a synthetic peptide (corresponding to residues
54–77) of murine MyD88, which specifically recognized the
30-kDa Flag-MyD88 protein expressed in 293T cells (Fig. 1B).
MyD88 was detected in many tissues with highest levels found
FIG. 2. MyD88 self-associates in yeast. Full-length MyD88 and MyD88 mutants are schematically represented. The black and gray rectangles
represent the death and Toll domains, respectively. MyD88 containing a point mutation, F56N, in the death domain (represented by a white circle)
is referred to as MyD88-lpr. Yeast CTY10–5d were co-transformed with expression vectors encoding the various GAL4 transcription activation
domain and LexA DNA-binding domain fusion proteins. Interaction of the proteins was assessed by b-galactosidase expression filter assays. 11
indicates strong color development within 60 min of the assay, and 2 indicates no development of color within 24 h. Interaction with the
intracellular domain of human human Fas (Fas-ID, residues 180–319), and with the empty vectors (pBTM116 and pGAD10) served as negative
controls. Interaction of TNF-R1-ID with TRADD and Fas-ID with Fas-ID served as positive controls (data not shown).
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in the ovary, adrenal gland, prostate, and thymus (Fig. 1C).
However, in certain tissues (kidney, liver, and spleen), which
have MyD88 transcript the protein was not detected, possibly
as a result of post-transcriptional regulation in these tissues.
MyD88 Forms Homodimers—Many adapter proteins in-
volved in signal transduction form homo- and heterotypic in-
teractions through like domains. As the death domain is a
region that frequently promotes such interactions, MyD88 was
analyzed for this capacity. Two-hybrid analysis, in vitro bind-
ing studies, and mammalian cell coimmunoprecipations re-
vealed that MyD88 forms homodimers (Figs. 2 and 3, A–C). To
assess whether the DD mediates self-association, various point
and deletion mutants of MyD88 were generated. Phe56 was
chosen for mutagenesis based on sequence alignment of the
MyD88 DD with the DD of Fas (3). A mutation at this position
corresponds to the lprcp mutation (33) known to abolish cyto-
toxic signaling of Fas, probably by disrupting the conformation
of the DD as revealed by recent NMR experiments (34). Muta-
tion of Phe56 to Asn inhibited association of full-length MyD88
with a truncated form containing the DD (MyD88-DD), indi-
cating that dimerization is mediated through the DD of
MyD88-DD. Surprisingly, MyD88-lpr was still capable of inter-
acting with MyD88 (Figs. 2 and 3A), suggesting the presence of
a second domain involved in self-association. Two constructs
encoding the Toll domain of MyD88 (MyD88-Toll and MyD88-
DDD) were therefore tested for their ability to bind to MyD88
(Figs. 2 and 3, A and B). MyD88-Toll bound to full-length
MyD88 and also to itself but not to MyD88-DD. However,
MyD88-Toll did not dimerize with either Toll-N (containing the
first half of the domain), Toll-C (containing the second half of
the domain), or Toll-D282–296 (missing 15 amino acids at the C
terminus), suggesting that the entire domain is required for
dimerization. The peptide deleted in Toll-D282–296 is homolo-
gous to a peptide in the Toll domain of the IL-1RI within which
are residues that have been shown to be critical for IL-1 sig-
naling (35).
DD-DD or Toll-Toll interactions mediate self-association of
MyD88, which, together, may result in stable association of
MyD88 proteins. It was also possible that the presence of these
two dimerization domains could allow the formation of higher
homo-oligomeric structures through head to tail aggregation.
To address this question, Flag-MyD88 expression constructs
were transfected into 293T cells, and cellular extracts were
fractionated by gel permeation chromatography. MyD88 eluted
as a defined peak with an apparent molecular mass of approx-
imately 60 kDa (corresponding to a 2.0-mer) suggesting that
MyD88 forms homodimers in vivo (Fig. 3C).
Heterotypic interactions between DD-containing proteins
are critical for linking adapter proteins in a number of signal-
ing pathways. Given the properties of MyD88, the ideal candi-
date for binding to its DD was the Ser/Thr kinase, IRAK which
also contains a N-terminal DD. We tested this possibility via
the yeast two-hybrid system and in mammalian cell coimmu-
noprecipation experiments using 293T cells overexpressing
MyD88 and IRAK, but did not detect an interaction. However,
while this manuscript was under revision, MyD88 was found to
associate with underphosphorylated IRAK (36). Wesche et al.
(36) also reported that overexpression of IRAK induces its
spontaneous autophosphorylation, thus precluding its associa-
tion with MyD88 in mammalian cell coimmunoprecipitation
experiments. Using the two-hybrid system we also tested other
FIG. 3. MyD88 forms homodimers. A, the interaction of MyD88
expressed as a GST fusion protein was assayed with 35S-labeled
MyD88, MyD88-lpr, or 35S-MyD88-DDD. The 35S-labeled proteins were
incubated with purified GST-MyD88 (left panel) or GST (right panel)
bound to glutathione-Sepharose beads and processed as described un-
der “Experimental Procedures.” Dried gels were exposed to x-ray film
overnight. B, coimmunoprecipitation of Myc-MyD88 with Flag-tagged
MyD88 proteins. 293T cells were transiently transfected with expres-
sion vectors (5 mg of each) encoding the indicated MyD88 proteins.
Anti-Flag (a-Flag) immunoprecipitates (IP) or total cell extracts were
analyzed by Western blotting (WB) with anti-Myc and anti-Flag anti-
bodies, respectively. C, lysate from 293T cells transfected with Flag-
MyD88 was fractionated on a Superdex-200 column. Every second
fraction was analyzed by Western blotting, and MyD88 was detected
with anti-Flag antibody. MyD88 migrates with a molecular mass of 30
kDa in SDS-PAGE. The position of the molecular mass markers (in
kDa) is indicated on the left-hand side for SDS-PAGE and at the top of
the figure for size exclusion chromatography.
FIG. 4. Overexpression of MyD88 activates JNK. A, detection of
activated JNK by phosphorylation of GST-c-JUN. Flag-tagged JNK
(Flag-JNK) and the indicated plasmids (2.5 mg each) were cotransfected
into 293T cells. JNK was immunoprecipated from cell lysates of the
transfected cells and assayed for kinase activity with GST-c-Jun. Top,
phosphorylation of GST-c-Jun. Bottom, expression of Flag-JNK. B, de-
tection of activated JNK by Western blot analysis. Equivalent amounts
of cell extracts from 293T cells transfected with JNK and MyD88
expression constructs (5 mg of each) were probed either with Anti-
ACTIVETM antibodies (Promega) that specifically recognize the active
phosphorylated form of JNK (upper panel) or with anti-JNK2 antibod-
ies (lower panel).
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known DD-containing receptor and adapter proteins (TNFR1,
TRAMP, FAS, FADD, TRADD, RIP, and RAIDD) for their
ability to interact with MyD88, but found no partners for
MyD88 among this group of proteins.
Signaling Activities of MyD88; Activation of JNK—To learn
more about the physiological activity(ies), we first tested
whether overexpression of MyD88 could induce cytotoxicity
like many of the DD-containing proteins. Surprisingly overex-
pression of MyD88 and MyD88-DD, but not MyD-lpr or MyD-
Toll induced apoptosis in 293T. The observed cytotoxicity was
apparent only after extended periods (36–50 h) following trans-
fection, therefore delayed by comparison with the cytotoxic
effects induced by the death receptors in similar experiments.
The cytotoxic effects of MyD88 were not apparent in other cell
types tested (COS, McF7), suggesting that MyD88-induced cy-
totoxicity in 293T cells may be a secondary effect due to high
levels of MyD88 in these cells.
Many signaling pathways which implicate DD-containing
adapter proteins lead to activation of the JNK/stress-activated
protein kinase pathway, which prototypically involves the se-
quential activation of MEKK1, SEK1, JNK, and c-Jun (37, 38).
To test the possibility that MyD88 might activate this kinase
cascade, 293T cells were cotransfected with MyD88 and Flag-
JNK. Flag-JNK was immunoprecipated from cell lysates and
tested for its activity using GST c-Jun as a substrate. MyD88,
but not MyD88-lpr induced JNK activation (Fig. 4A). Activa-
tion of JNK was also detected by Western analysis using an
antibody that specifically recognizes the active, phosphorylated
form of the kinase. MyD88 and MyD88N significantly induced
activation of JNK (Fig. 4B). That neither MyD88-lpr nor
MyD88-Toll activated JNK suggests that DD of MyD88 is crit-
ical for this activity.
Activation of the Transcription Factor NF-kB—Both the
death and Toll domains represent motifs that are often in-
volved in NF-kB activation. To test whether MyD88 could
activate NF-kB electrophoretic mobility shift assays were car-
ried out on cellular extracts from transfected 293 cells. Over-
expression of MyD88 or MyD88-DD led to significant activation
of NF-kB in the absence of exogenous stimuli (such as TNF-a or
IL-1) (Fig. 5A), whereas in cells transfected with empty expres-
sion vector, MyD88-lpr or MyD88-DDD specific NF-kB com-
plexes were not detected, suggesting that the DD of MyD88 is
responsible for this activation. Supershift experiments with
p65 antibody demonstrated that p65 is a component of the
activated NF-kB complex (Fig. 5A, right panel).
FIG. 5. NF-kB is activated by MyD88 overexpression. A, Electrophoretic mobility shift assay of NF-kB activation in 293T cells. 293 cells were
transfected with 6 mg of each expression vector. Total cell extracts were prepared 24 h after transfection, and 10-mg aliquots were combined with
the 32P-labeled NF-kB oligonucleotide probe. Supershift reactions were performed by adding 1 ml of preimmune serum or anti-p65 serum at the
same time as the probe. Specific NF-kB complexes are indicated by arrows. B, activation of NF-kB by MyD88 deletion mutants. 293T cells were
transfected with 1 mg of a NF-kB luciferase reporter plasmid (pNF-kBLuc), 0.5 mg of pCMV b-gal, and the indicated MyD88 constructs (1.5 mg of
each). The expression levels of the various MyD88 constructs were examined by Western blot analysis with anti-Flag antibodies (lower panel). C,
effect of increasing MyD88 expression on NF-kB activity. NF-kB assays were performed following cotransfection of 293T cells with 1 mg of
pNF-kBLuc, 0.5 mg of pCMV b-gal, and the indicated amounts of pMyD88 to give 3 mg of total DNA. D, the specificity of NF-kB activation. 293T
cells (2 3 105) were transfected with 1 mg of HIV promoter derived NF-kB luciferase reporter (HIV-Luc) or a reporter plasmid containing a point
mutation in the NF-kB site (HIV-84 Luc) and with 0.5 mg of pCMV b-gal, 1.5 mg of MyD88 (dark shading); or 1.5 mg of empty vector (light shading).
Luciferase activities in B–D were determined 24 h after transfection and normalized on the basis of b-galactosidase values. Values shown are
averages for representative experiments in which each transfection was carried out in duplicate.
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We also examined the ability of MyD88 to activate a NF-kB-
dependent reporter plasmid (pNF-kBLuc) by cotransfecting
293T cells with pNF-kBLuc and the various MyD88 constructs
(Fig. 5B). In agreement with the electrophoretic mobility shift
assays, MyD88 and MyD88-DD strongly induced NF-kB acti-
vation in 293 cells, and the mutants MyD88-lpr and MyD88-
DDD were inactive. MyD88 induced the activity of pNF-kBLuc
in a dose-dependent manner (Fig. 5C) and failed to activate
pHIV-84, a luciferase reporter plasmid containing a mutation
in the NF-kB elements of the HIV promoter, confirming the
specificity of this activation (Fig. 5D). NF-kB activation follow-
ing transient transfection with the MyD88 expression vector
was also observed in HeLa and McF7 cells (data not shown).
MyD88 Is an Adaptor Protein in the IL-1-signaling Path-
way—The observations that MyD88 efficiently induced NF-kB
and JNK activation together with its dual domain structure
hinted at a role for MyD88 in IL-1 signaling. TRAF6 is required
for IL-1-induced NF-kB activation, whereas TRAF2 has been
implicated in NF-kB activation signaled through TNF (39–41).
Dominant negative versions of these TRAFs are known to block
IL-1- and TNF-induced NF-kB activation, respectively. TRAF6
(287–522) but not TRAF2 (87–501) significantly inhibited
MyD88-induced NF-kB activation in 293T, suggesting that
MyD88 is most likely involved in IL-1 signaling and that
TRAF6 functions downstream of MyD88 (Fig. 6A). Dominant
negative IRAK (1–217) also inhibited MyD88-induced NF-kB
activation, suggesting that MyD88 functions upstream of IRAK
(Fig. 6A).
If MyD88 is a mediator of IL-1 signaling, we reasoned that a
dominant negative version of it should block IL-1-induced
NF-kB and JNK activity. As the DD of MyD88 is essential for
these activities, we tested whether MyD88-lpr could act to
block IL-1-induced NF-kB and JNK activation. When a cell line
(293 Myc-IL-1RI), which overexpressses the IL-1RI and re-
sponses to IL-1 treatment by activating the NF-kB-dependent
reporter plasmid, approximately 20-fold was transfected with
MyD88-lpr; IL-1-dependent NF-kB activation was inhibited in
a dose-dependent manner (Fig. 6B). Overexpression of MyD88-
lpr did not affect NF-kB activation signaled by TNF or induced
by coexpression of TRAMP, demonstrating that the dominant-
negative effect of the MyD88 mutant to IL-1 signaling was
specific (Fig. 6B). MyD88-Toll overexpression also blocked IL-
1-mediated NF-kB activation (Fig. 6B). IL-1-induced JNK ac-
tivation was similarly inhibited in 293 IL-1RI cells by overex-
pression of MyD88-lpr or -Toll (Fig. 6C).
The ability of MyD88-Toll to block these IL-1-induced signals
suggested the possibility that MyD88 may directly associate
with the IL-1RI and/or IL-1RAcP. We tested this possibility
using the yeast two-hybrid system, but did not detect an asso-
ciation of MyD88 with either of the receptor chains. Also an
association between MyD88 and one of the receptor chains
alone was also not detected in coimmunoprecipitation experi-
FIG. 6. Ordering of MyD88 in the
IL-1R pathway. A, dominant negative
forms of TRAF6 (287–522) and IRAK (1–
217) inhibit MyD88 induced NF-kB acti-
vation. 293T cells were cotransfected with
MyD88 (0.3 mg), the indicated concentra-
tions of TRAF6 (287–522) (n), TRAF2
(87–501) (h), or IRAK (1–217) (u), and 1
mg of pNF-kBLuc and 0.5 mg of pCMV
b-gal. Luciferase activity was measured
32 h after transfection and normalized on
the basis of b-galactosidase values. Rela-
tive luciferase activity is reported as per-
cent induction. B, dominant negative ver-
sions of MyD88 inhibit IL-1-induced
NF-kB activation. A stable cell line ex-
pressing the IL-1RI (293 Myc-IL-1RI) was
transfected with the indicated concentra-
tions of MyD88-lpr (n) or MyD88-Toll (h)
and with 1 mg of pNF-kBLuc and 0.5 mg of
pCMV b-gal. 40 h after transfection the
cells were treated with IL-1b (10 ng/ml)
for an additional 6 h before harvesting. u,
vector. Values shown in A and B are av-
erages for representative experiments in
which each transfection was carried out
in duplicate. C, dominant negative ver-
sions of MyD88 inhibit IL-1 induced JNK
activity. 293 myc-IL-1RI cells were trans-
fected with Flag-JNK (3 mg) and the indi-
cated MyD88 constructs (2 mg each). 40 h
after transfection the cells were treated
with IL-1b (20 ng/ml) for an additional 7 h
before harvesting. Activated JNK was de-
tected by Western analysis in cellular ex-
tracts probed with Anti-ACTIVETM anti-
bodies (Promega) that specifically
recognize the active phosphorylated form
of JNK (upper panel) or with anti-JNK2
antibodies (lower panel). D, MyD88 asso-
ciates with the IL-1RI complex in an IL-
1b-dependent manner. Western analysis
with anti-VSV antibody was used to de-
tect MyD88 in the IL-1R complex precip-
itated from IL-1-treated (1) or untreated
(2) 293T cells (3 3 106) cotransfected
with VSV-MyD88, Flag-IL-1RAcP, and
Myc-IL-1RI (5 mg of each).
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ments using 293T cells transfected with MyD88 and IL-1RI or
IL-1RAcP (data not shown). However, in similar experiments
using 293T cells transfected with MyD88 and both of the re-
ceptor chains, MyD88 was detected in the IL-1RI complex in an
IL-1-dependent manner (Fig. 6D).
DISCUSSION
IL-1 is a potent cytokine that elicits multiple diverse effects
on immunological and inflammatory processes. It exerts its
various biological activities mainly through activation of the
transcription factors NF-kB and activating protein 1, which
regulate the expression of numerous genes involved in these
processes. Signaling cascades leading to the activation of these
transcription factors are initiated by IL-1-induced complex for-
mation of the IL-1RI and the IL-1RAcP (15–17). This in turn
leads to IRAK recruitment to the receptor complex where IRAK
becomes highly phosphorylated (19). Phosphorylated IRAK is
then believed to dissociate from the receptor complex and in-
teract with TRAF6, and it becomes rapidly degraded via a
proteasome-dependent pathway (39, 42). The results described
above show that overexpression of MyD88 activates both
NF-kB (in a pathway upstream of IRAK and TRAF6) and JNK
(activating protein 1) and therefore mimics these two IL-1-
induced cellular responses. Moreover, MyD88 associates with
the IL-1RI complex in an IL-1-dependent manner and, domi-
nant-negative forms of MyD88 (MyD88-lpr and MyD88-Toll)
block IL-1 signaling. Our findings therefore demonstrate that
MyD88 has an important role in mediating the cellular re-
sponses to this cytokine.
How can our findings be incorporated into the current model
of IL-1 signaling? Experiments with the dominant negative
mutants of MyD88 (MyD88-lpr and MyD88-Toll) indicate the
MyD88-Toll domain links MyD88 with upstream components
of the IL-1 pathway. Indeed, the Toll domain of MyD88 has
recently been demonstrated to link MyD88 with the IL-1R
complex (36). Despite the ability of MyD88-Toll to mediate
homophilic interactions between MyD88 molecules, we and
others (36) did not detect an interaction of MyD88 with either
of the two receptor chains alone. MyD88, however, associates
with the receptor complex after IL-1 stimulation and thus
aggregation of receptor chains (36). This suggests the possibil-
ity that IL-1-induced heterocomplex formation induces associ-
ation of the IL-1RI and IL-1RAcP via their respective Toll
domains creating a novel interaction surface, in an analogous
manner to those formed through DD-DD interactions in Fas- or
TNF-R1-signaling complexes, that allows for the recruitment of
MyD88 through homophilic interactions. We have shown that
MyD88 forms homodimers through DD-DD and Toll-Toll inter-
actions and therefore is probably recruited as a dimer to the
IL-1RI complex.
The MyD88-DD is critical for MyD88-induced activation of
NF-kB and JNK. This suggests that the DD engages down-
stream proteins involved in these pathways. Recently it was
demonstrated that a kinase-defective form of IRAK (IRAK
K239S) and a novel IRAK-like molecule termed IRAK-2, also
involved in IL-1-induced NF-kB activation, interact with
MyD88 (36, 43). MyD88 associates with both of these proteins
through its N-terminal domain and in the case of IRAK also via
interactions mediated through its Toll domain (36, 43). MyD88
therefore utilizes its dual domain organization to function as
an adapter linking Toll- and death-containing protein modules
in IL-1-signaling cascades.
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